Your browser doesn't support javascript.
loading
Chronotype, Longitudinal Volumetric Brain Variations Throughout Adolescence, and Depressive Symptom Development.
Vulser, Hélène; Lemaître, Hervé S; Guldner, Stella; Bezivin-Frère, Pauline; Löffler, Martin; Sarvasmaa, Anna S; Massicotte-Marquez, Jessica; Artiges, Eric; Paillère Martinot, Marie-Laure; Filippi, Irina; Miranda, Ruben; Stringaris, Argyris; van Noort, Betteke Maria; Penttilä, Jani; Grimmer, Yvonne; Becker, Andreas; Banaschewski, Tobias; Bokde, Arun L W; Desrivières, Sylvane; Fröhner, Juliane H; Garavan, Hugh; Grigis, Antoine; Gowland, Penny A; Heinz, Andreas; Papadopoulos Orfanos, Dimitri; Poustka, Luise; Smolka, Michael N; Spechler, Philip A; Walter, Henrik; Whelan, Robert; Schumann, Gunter; Flor, Herta; Martinot, Jean-Luc; Nees, Frauke.
Afiliação
  • Vulser H; Institute of Cognitive and Clinical Neuroscience, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Germany; AP-HP Sorbonne Université, Pitié-Salpêtrière Hospital, France. Electronic address: helene.vulser@aphp.fr.
  • Lemaître HS; Institut des Maladies Neurodégénératives, UMR 5293, CNRS, CEA, Université de Bordeaux, Bordeaux, France.
  • Guldner S; Institute of Cognitive and Clinical Neuroscience, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Germany.
  • Bezivin-Frère P; Institut National de la Santé et de la Recherche Médicale, INSERM U1299 A10 "Trajectoires développementales en psychiatrie," Ecole Normale supérieure Paris-Saclay, Université Paris-Saclay, Université de Paris, CNRS UMR9010, Centre Borelli, Gif-sur-Yvette, France.
  • Löffler M; Institute of Cognitive and Clinical Neuroscience, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Germany.
  • Sarvasmaa AS; National Institute for Health and Welfare, Mental Health Unit, Helsinki, Finland, and the University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
  • Massicotte-Marquez J; Institut National de la Santé et de la Recherche Médicale, INSERM U1299 A10 "Trajectoires développementales en psychiatrie," Ecole Normale supérieure Paris-Saclay, Université Paris-Saclay, Université de Paris, CNRS UMR9010, Centre Borelli, Gif-sur-Yvette, France.
  • Artiges E; Institut National de la Santé et de la Recherche Médicale, INSERM U1299 A10 "Trajectoires développementales en psychiatrie," Ecole Normale supérieure Paris-Saclay, Université Paris-Saclay, Université de Paris, CNRS UMR9010, Centre Borelli, Gif-sur-Yvette, France; EPS Barthélémy Durand, Etampes, Fran
  • Paillère Martinot ML; AP-HP Sorbonne Université, Pitié-Salpêtrière Hospital, France; Institut National de la Santé et de la Recherche Médicale, INSERM U1299 A10 "Trajectoires développementales en psychiatrie," Ecole Normale supérieure Paris-Saclay, Université Paris-Saclay, Université de Paris, CNRS UMR9010, Centre Borell
  • Filippi I; Institut National de la Santé et de la Recherche Médicale, INSERM U1299 A10 "Trajectoires développementales en psychiatrie," Ecole Normale supérieure Paris-Saclay, Université Paris-Saclay, Université de Paris, CNRS UMR9010, Centre Borelli, Gif-sur-Yvette, France.
  • Miranda R; AP-HP Sorbonne Université, Pitié-Salpêtrière Hospital, France.
  • Stringaris A; National Institute of Mental Health, Bethesda, Maryland.
  • van Noort BM; MSB Medical School Berlin, Hochschule für Gesundheit und Medizin, Siemens Villa, Berlin.
  • Penttilä J; Psychosocial Services Adolescent Outpatient Clinic, Lahti, Finland.
  • Grimmer Y; Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
  • Becker A; University Medical Center, Göttingen.
  • Banaschewski T; Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
  • Bokde ALW; School of Medicine and Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland.
  • Desrivières S; Centre for Population Neuroscience and Precision Medicine (PONS), Institute of Psychiatry, Psychology & Neuroscience, SGDP Centre, King's College London, London, United Kingdom.
  • Fröhner JH; Technische Universität Dresden, Dresden, Germany.
  • Garavan H; University of Vermont, Burlington.
  • Grigis A; NeuroSpin, Commissariat à l'Energie Atomique, Université Paris-Saclay, Gif-sur-Yvette, France.
  • Gowland PA; Sir Peter Mansfield Imaging Centre School of Physics and Astronomy, University of Nottingham, University Park, Nottingham, United Kingdom.
  • Heinz A; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
  • Papadopoulos Orfanos D; NeuroSpin, Commissariat à l'Energie Atomique, Université Paris-Saclay, Gif-sur-Yvette, France.
  • Poustka L; University Medical Centre Göttingen, Göttingen, Germany.
  • Smolka MN; Technische Universität Dresden, Dresden, Germany.
  • Spechler PA; University of Vermont, Burlington.
  • Walter H; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
  • Whelan R; School of Psychology and Global Brain Health Institute, Trinity College Dublin, Ireland.
  • Schumann G; Centre for Population Neuroscience and Precision Medicine (PONS), Institute of Psychiatry, Psychology & Neuroscience, SGDP Centre, King's College London, London, United Kingdom, the PONS Research Group, Campus Charite Mitte, Humboldt University, Berlin, Leibniz Institute for Neurobiology, Magdeb
  • Flor H; Institute of Cognitive and Clinical Neuroscience, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Germany; School of Social Sciences, University of Mannheim, Germany.
  • Martinot JL; Institut National de la Santé et de la Recherche Médicale, INSERM U1299 A10 "Trajectoires développementales en psychiatrie," Ecole Normale supérieure Paris-Saclay, Université Paris-Saclay, Université de Paris, CNRS UMR9010, Centre Borelli, Gif-sur-Yvette, France.
  • Nees F; Institute of Cognitive and Clinical Neuroscience, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Germany; Institute of Medical Psychology and Medical Sociology, University Medical Center Schleswig Holstein, Kiel University, Kiel, Germany, and the Central Institu
J Am Acad Child Adolesc Psychiatry ; 62(1): 48-58, 2023 01.
Article em En | MEDLINE | ID: mdl-35714839
OBJECTIVE: Adolescence is a critical period for circadian rhythm, with a strong shift toward eveningness around age 14. Also, eveningness in adolescence has been found to predict later onset of depressive symptoms. However, no previous study has investigated structural variations associated with chronotype in early adolescence and how this adds to the development of depressive symptoms. METHOD: Assessment of 128 community-based adolescents (51% girls) at age 14 and 19 years was performed. Using whole-brain voxel-based morphometry, baseline (at age 14) regional gray matter volumes (GMVs), follow-up (at age 19) regional GMVs, and longitudinal changes (between 14 and 19) associated with Morningness/Eveningness Scale in Children score and sleep habits at baseline were measured. The association of GMV with depressive symptoms at 19 years was studied, and the role of potential clinical and genetic factors as mediators and moderators was assessed. RESULTS: Higher eveningness was associated with larger GMV in the right medial prefrontal cortex at ages 14 and 19 in the whole sample. GMV in this region related to depressive symptoms at age 19 in catechol-O-methyltransferase (COMT) Val/Val, but not in Met COMT, carriers. Larger GMV also was observed in the right fusiform gyrus at age 14, which was explained by later wake-up time during weekends. CONCLUSION: In adolescence, eveningness and its related sleep habits correlated with distinct developmental patterns. Eveningness was specifically associated with GMV changes in the medial prefrontal cortex; this could serve as a brain vulnerability factor for later self-reported depressive symptoms in COMT Val/Val carriers.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Catecol O-Metiltransferase / Depressão Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Catecol O-Metiltransferase / Depressão Idioma: En Ano de publicação: 2023 Tipo de documento: Article